Lo T C, Salzman F A, Swartz M R
Otolaryngol Clin North Am. 1985 Aug;18(3):521-31.
Achievements in radiotherapy of head and neck cancer continue. During the past decade, bench marks have been established for certain early staged malignancies. Technical advances have occurred in higher energy accelerators with the development of dual photon and medium-range electron machines. Imaging technology has augmented precision tumor localization and staging, and its marriage to computerized treatment planning is leading the way toward an optimization of delivered radiation dose to the tumor volume. Neutron therapy is finding a definite place in moderately advanced head and neck cancers, and its wider use awaits further developments in compact neutron generators. Hyperthermia combined with photon radiation is undergoing serious clinical trials, and this combination appears to be most promising. The search for radiation sensitizers to enhance tumor destruction and for radioprotectors for normal tissue continues. Progress in the latter appears encouraging. Burgeoning radiobiologic data have led the way to several dose fractionation schemes, and the most promising clinically appears to be hyperfractionation. Combinations of surgery and radiotherapy have improved cure rates in moderately advanced malignancies, but a preference between preoperative and postoperative radiotherapy in specific sites is still controversial. The medical oncologist has become a valued member of the interdisciplinary team rather than remaining solely the recipient of failed radiotherapeutic and surgical patients. There is a keener awareness of the difficulties and intricacies involved in the construction and evaluation of clinical trials and results.
头颈癌放射治疗领域持续取得进展。在过去十年中,已为某些早期恶性肿瘤确立了基准。随着双光子和中程电子机器的发展,高能加速器技术取得了进步。成像技术提高了肿瘤定位和分期的精准度,并且与计算机化治疗计划相结合,正引领着向肿瘤体积输送优化辐射剂量的方向发展。中子治疗在中晚期头颈癌中占据了一定地位,其更广泛的应用有待紧凑型中子发生器的进一步发展。热疗联合光子辐射正在进行严格的临床试验,这种联合似乎最具前景。寻找增强肿瘤破坏作用的辐射增敏剂以及保护正常组织的放射防护剂的工作仍在继续。后者的进展似乎令人鼓舞。大量的放射生物学数据催生了几种剂量分割方案,其中最具临床前景的似乎是超分割放疗。手术与放疗相结合提高了中晚期恶性肿瘤的治愈率,但在特定部位术前放疗和术后放疗的选择仍存在争议。医学肿瘤学家已成为多学科团队中有价值的成员,而不再仅仅是放疗和手术失败患者的接收者。人们更加敏锐地意识到临床试验构建和评估以及结果中所涉及的困难和复杂性。